Incretin-based Therapy in Late Preclinical Type 1 Diabetes

NCT02898506 · Completed

Last updated 2026-05-28

This clinical trial is testing whether incretin-based therapy can help preserve insulin production in people who are in the late stages before developing type 1 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind prevention study

Participants 13 people

Who can join Ages 10–30 · all sexes

Timeline Started 2016-03 · est. completion 2021-06

Where 4 sites · Finland, Sweden

What this study is testing ClinicalTrials.gov NCT02898506 ↗

Description as written by the study sponsor.

The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.

Treatments tested

Victoza® Drug

Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
Placebo Drug

Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.

Main thing measured	FPIR (1+3min serum insulin level after iv glucose infusion)
Sponsor	University of Oulu
Conditions studied	Type 1 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02898506 ↗